Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises VNV Global in relation to the groups change of domicile from Bermuda to Sweden.
Mandate

Vinge advises VNV Global in relation to the groups change of domicile from Bermuda to Sweden. 

June 10, 2020 Capital Markets and Public M&A Corporate Tax

Vinge has advised VNV Global in connection with the process of changing the group’s domicile from Bermuda to Sweden (the “Redomestication”). The Redomestication is carried out by way of a scheme of arrangement under Bermuda law, whereby Swedish Depository Receipts in VNV Global Ltd. will be exchanged for shares in the Swedish group entity VNV Global AB (publ) that, following the Redomestication, will constitute the new parent company of the group. The shares of VNV Global AB (publ) will be listed on the main market of Nasdaq Stockholm.

VNV Global Ltd. is an investment company with the business concept of using experience, expertise and a widespread network to identify and invest in assets with considerable potential for value appreciation. The company has a special focus on online marketplaces and businesses with strong network effects.
 
Vinge’s team has primarily consisted of Jesper Schönbeck, Joel Wahlberg, Boris Kotur, Annika Nyberg Ekenberg, William Kåge, Linnéa Sellström, Joel Magnusson, Emil Lindwall, Eléonore Friberg, Mikaela Falkner (Capital Markets & Public M&A) and Maria Schultzberg (tax).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025